Overview

The International CML Foundation (iCMLf) is on a mission to improve outcomes for patients with CML, globally.

Founded by a dedicated group of hematologists, we are committed to ensuring every patient with CML, no matter where they are in the world, receives the best possible treatment and care. We foster international collaboration to elevate knowledge, enhance diagnostics, and drive ground-breaking research.

As a unique charitable foundation focused solely on CML, we strive to empower physicians, researchers, patients and caregivers alike, in the collective pursuit of a cure for CML.

The iCMLf is the only organisation that brings together the CML community of investigators, treating physicians, and patients… It’s not just made of top academic centers. It’s made of everybody all over the world that just has a passion and interest in CML.

- Professor Jorges Cortes - iCMLf Chairman

Our mission

Improving outcomes for patients with CML globally.

Our vision

Everyone with CML has equal access to expert treatment, diagnosis and care, ensuring that a cure is not merely a hope but a reality

Our inspiration

The iCMLf was founded with a shared commitment to improving the lives of those affected by CML worldwide. Emerging in the early 2000s and officially established in 2009 by a group of dedicated hematologists, the foundation was inspired by the urgent need to address global disparities in CML care. Motivated by the challenges faced by physicians, particularly in low- and middle-income countries, the iCMLf strives to bridge gaps in knowledge and resources, fostering innovation, collaboration, and clinical excellence.

Looking to the future, the iCMLf remains steadfast in its mission to ensure that geographic and socioeconomic barriers do not limit access to quality CML care. Through advocacy, research, and global partnerships, the foundation envisions a world where CML is not only effectively managed but ultimately cured. Guided by this vision, the iCMLf continues to champion efforts that drive meaningful change and improve outcomes for patients worldwide.

The improved survival in CML is directly attributable to the use of tyrosine kinase inhibitors is so dramatic that these new agents must be made available to the greatest possible number of eligible patients as rapidly as possible throughout the whole world.

- Professor John Goldman (2010) - Co-Founder and First Chairman of the iCMLf

Our values

We are driven by a set of core values:

Knowledge sharing

Information and expertise are exchanged freely to empower clinicians and healthcare professionals, researchers and patients worldwide.

Collaboration

Promoting partnerships with clinicians and healthcare professionals, scientists and researchers, medical associations, patient advocates and patients, and organisations to collectively advance CML care and research.

Innovation

Creative thinking, pioneering solutions, and pushing the boundaries of traditional approaches bring about transformative change in the field of CML.

Excellence

Excellence in all our endeavours, prioritising quality in everything we do, from working with global experts to cutting-edge scientific research, in order to achieve the best possible outcomes for individuals affected by CML.

Compassion

The iCMLf values empathy and understanding, recognising the human impact of living with CML and fostering a caring community by focusing on people, not patients.

Hope

The iCMLf embraces hope, providing the best possible care, optimising treatment outcomes, and believing in the possibility of a cure, inspiring optimism for those facing the challenges of this disease.

Our partners

Corporate support